Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma

Differentiated thyroid carcinoma (DTC) comprises over 90% of thyroid tumors and includes papillary and follicular carcinomas. Patients with DTC have an excellent prognosis, with a 10-year survival rate of over 90%. However, the risk of recurrent tumor ranges between 5% and 30% within 10 years of the...

Full description

Bibliographic Details
Main Authors: Shorook Na’ara, Moran Amit, Eran Fridman, Ziv Gil
Format: Article
Language:English
Published: Rambam Health Care Campus 2016-01-01
Series:Rambam Maimonides Medical Journal
Subjects:
Online Access:http://rmmj.org.il/Pages/ArticleHTM.aspx?manuId=546
id doaj-b95bd0b85e54441e9dcbd650c6e89265
record_format Article
spelling doaj-b95bd0b85e54441e9dcbd650c6e892652020-11-24T22:46:58ZengRambam Health Care CampusRambam Maimonides Medical Journal2076-91722016-01-0171e000610.5041/RMMJ.10233Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid CarcinomaShorook Na’ara0Moran Amit1Eran Fridman2Ziv Gil3The Head and Neck Center, Department of Otolaryngology Head and Neck Surgery, Rambam Healthcare Campus, Clinical Research Institute at Rambam, Rappaport Institute of Medicine and Research, The Technion, Israel Institute of Technology, Haifa, IsraelThe Head and Neck Center, Department of Otolaryngology Head and Neck Surgery, Rambam Healthcare Campus, Clinical Research Institute at Rambam, Rappaport Institute of Medicine and Research, The Technion, Israel Institute of Technology, Haifa, IsraelThe Head and Neck Center, Department of Otolaryngology Head and Neck Surgery, Rambam Healthcare Campus, Clinical Research Institute at Rambam, Rappaport Institute of Medicine and Research, The Technion, Israel Institute of Technology, Haifa, IsraelThe Head and Neck Center, Department of Otolaryngology Head and Neck Surgery, Rambam Healthcare Campus, Clinical Research Institute at Rambam, Rappaport Institute of Medicine and Research, The Technion, Israel Institute of Technology, Haifa, IsraelDifferentiated thyroid carcinoma (DTC) comprises over 90% of thyroid tumors and includes papillary and follicular carcinomas. Patients with DTC have an excellent prognosis, with a 10-year survival rate of over 90%. However, the risk of recurrent tumor ranges between 5% and 30% within 10 years of the initial diagnosis. Cervical lymph node disease accounts for the majority of recurrences and in most cases is detected during follow-up by ultrasound or elevated levels of serum thyroglobulin. Recurrent disease is accompanied by increased morbidity. The mainstay of treatment of nodal recurrence is surgical management. We provide an overview of the literature addressing surgical management of recurrent or persistent lymph node disease in patients with DTC.http://rmmj.org.il/Pages/ArticleHTM.aspx?manuId=546Lymph nodespersistent
collection DOAJ
language English
format Article
sources DOAJ
author Shorook Na’ara
Moran Amit
Eran Fridman
Ziv Gil
spellingShingle Shorook Na’ara
Moran Amit
Eran Fridman
Ziv Gil
Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma
Rambam Maimonides Medical Journal
Lymph nodes
persistent
author_facet Shorook Na’ara
Moran Amit
Eran Fridman
Ziv Gil
author_sort Shorook Na’ara
title Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma
title_short Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma
title_full Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma
title_fullStr Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma
title_full_unstemmed Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma
title_sort contemporary management of recurrent nodal disease in differentiated thyroid carcinoma
publisher Rambam Health Care Campus
series Rambam Maimonides Medical Journal
issn 2076-9172
publishDate 2016-01-01
description Differentiated thyroid carcinoma (DTC) comprises over 90% of thyroid tumors and includes papillary and follicular carcinomas. Patients with DTC have an excellent prognosis, with a 10-year survival rate of over 90%. However, the risk of recurrent tumor ranges between 5% and 30% within 10 years of the initial diagnosis. Cervical lymph node disease accounts for the majority of recurrences and in most cases is detected during follow-up by ultrasound or elevated levels of serum thyroglobulin. Recurrent disease is accompanied by increased morbidity. The mainstay of treatment of nodal recurrence is surgical management. We provide an overview of the literature addressing surgical management of recurrent or persistent lymph node disease in patients with DTC.
topic Lymph nodes
persistent
url http://rmmj.org.il/Pages/ArticleHTM.aspx?manuId=546
work_keys_str_mv AT shorooknaara contemporarymanagementofrecurrentnodaldiseaseindifferentiatedthyroidcarcinoma
AT moranamit contemporarymanagementofrecurrentnodaldiseaseindifferentiatedthyroidcarcinoma
AT eranfridman contemporarymanagementofrecurrentnodaldiseaseindifferentiatedthyroidcarcinoma
AT zivgil contemporarymanagementofrecurrentnodaldiseaseindifferentiatedthyroidcarcinoma
_version_ 1725682914586263552